Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

US12214037B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Jennifer Brogdon · Cambridge, US
• Eugene Choi · Cambridge, US
• Hilmar Erhard Ebersbach · Basel, CH
• David Glass · Cambridge, US
• Heather Huet · Cambridge, US
• Carl H. June · Yeadon, US
• Joan Mannick · Cambridge, US
• Michael C. Milone · Cherry Hill, US
• Leon Murphy · Cambridge, US
• Gabriela Plesa · Blue Bell, US
• Celeste Richardson · Cambridge, US
• Marco Ruella · Ardmore, US
• Reshma Singh · Cambridge, US
• Yongqiang Wang · Shanghai, CN
• Qilong Wu · Shanghai, CN

Key dates

• Filing date: Jun 25, 2021
• Grant date: Feb 4, 2025
• Expiry date: Dec 17, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N15/63
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.